Skip to main content
Top
Published in: Inflammation 4/2011

01-08-2011

Nicotine Exerts an Anti-inflammatory Effect in a Murine Model of Acute Lung Injury

Authors: Jon Mabley, Sevelanne Gordon, Pal Pacher

Published in: Inflammation | Issue 4/2011

Login to get access

Abstract

Activation of the cholinergic anti-inflammatory pathway through direct activation of nicotinic acetylcholine receptors on immune cells can inhibit pro-inflammatory chemokine and cytokine release and thereby protect in a variety of inflammatory diseases. The aim of this study was to investigate whether nicotine treatment protected against acute lung inflammation. Mice challenged with intratracheal lipopolysaccharide (LPS, 50 μg) were treated with nicotine (0.2 or 0.4 mg/kg, sc). After 24 h, bronchoalveolar lavage fluid (BALF) was obtained to measure leukocyte infiltration, lung edema, and pro-inflammatory chemokine (MIP-1α, MIP-2, and eotaxin) and cytokine (IL-1, IL-6, and TNF-α) levels. Nicotine treatment reduced the LPS-mediated infiltration of leukocytes and edema as evidenced by decreased BALF inflammatory cells, myeloperoxidase, and protein. Nicotine also downregulated lung production of pro-inflammatory chemokines and cytokines. These data support the proposal that activation of the cholinergic anti-inflammatory pathway may represent a useful addition to the therapy of acute respiratory distress syndrome.
Literature
1.
go back to reference Artigas, A., G.R. Bernard, J. Carlet, et al. 1998. The American-European Consensus Conference on ARDS, part 2. Ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling. Intensive Care Medicine 24: 378–398.PubMedCrossRef Artigas, A., G.R. Bernard, J. Carlet, et al. 1998. The American-European Consensus Conference on ARDS, part 2. Ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling. Intensive Care Medicine 24: 378–398.PubMedCrossRef
2.
go back to reference Kollef, M.H., and D.P. Schuster. 1995. The acute respiratory distress syndrome. The New England Journal of Medicine 332: 27–37.PubMedCrossRef Kollef, M.H., and D.P. Schuster. 1995. The acute respiratory distress syndrome. The New England Journal of Medicine 332: 27–37.PubMedCrossRef
3.
go back to reference Abraham, E., A. Carmody, R. Shenkar, and J. Arcaroli. 2000. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 279: L1137–L1145.PubMed Abraham, E., A. Carmody, R. Shenkar, and J. Arcaroli. 2000. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 279: L1137–L1145.PubMed
4.
go back to reference Strieter, R.M., S.L. Kunkel, M.P. Keane, and T.J. Standiford. 1999. Chemokines in lung injury: Thomas A. Neff Lecture. Chest 116: 103S–110S.PubMedCrossRef Strieter, R.M., S.L. Kunkel, M.P. Keane, and T.J. Standiford. 1999. Chemokines in lung injury: Thomas A. Neff Lecture. Chest 116: 103S–110S.PubMedCrossRef
5.
go back to reference Meduri, G.U., S. Headley, G. Kohler, et al. 1995. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107: 1062–1073.PubMedCrossRef Meduri, G.U., S. Headley, G. Kohler, et al. 1995. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107: 1062–1073.PubMedCrossRef
6.
go back to reference Takala, A., I. Jousela, O. Takkunen, et al. 2002. A prospective study of inflammation markers in patients at risk of indirect acute lung injury. Shock 17: 252–257.PubMedCrossRef Takala, A., I. Jousela, O. Takkunen, et al. 2002. A prospective study of inflammation markers in patients at risk of indirect acute lung injury. Shock 17: 252–257.PubMedCrossRef
7.
go back to reference Peng, X., R.E. Abdulnour, S. Sammani, et al. 2005. Inducible nitric oxide synthase contributes to ventilator-induced lung injury. American Journal of Respiratory and Critical Care Medicine 172: 470–479.PubMedCrossRef Peng, X., R.E. Abdulnour, S. Sammani, et al. 2005. Inducible nitric oxide synthase contributes to ventilator-induced lung injury. American Journal of Respiratory and Critical Care Medicine 172: 470–479.PubMedCrossRef
8.
go back to reference Borron, P., J.C. McIntosh, T.R. Korfhagen, J.A. Whitsett, J. Taylor, and J.R. Wright. 2000. Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. American Journal of Physiology. Lung Cellular and Molecular Physiology 278: L840–L847.PubMed Borron, P., J.C. McIntosh, T.R. Korfhagen, J.A. Whitsett, J. Taylor, and J.R. Wright. 2000. Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. American Journal of Physiology. Lung Cellular and Molecular Physiology 278: L840–L847.PubMed
9.
go back to reference Tracey, K.J. 2007. Physiology and immunology of the cholinergic antiinflammatory pathway. The Journal of Clinical Investigation 117: 289–296.PubMedCrossRef Tracey, K.J. 2007. Physiology and immunology of the cholinergic antiinflammatory pathway. The Journal of Clinical Investigation 117: 289–296.PubMedCrossRef
10.
go back to reference Borovikova, L.V., S. Ivanova, M. Zhang, et al. 2000. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458–462.PubMedCrossRef Borovikova, L.V., S. Ivanova, M. Zhang, et al. 2000. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458–462.PubMedCrossRef
11.
go back to reference van Westerloo, D.J., I.A. Giebelen, S. Florquin, et al. 2005. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. The Journal of Infectious Diseases 191: 2138–2148.PubMedCrossRef van Westerloo, D.J., I.A. Giebelen, S. Florquin, et al. 2005. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. The Journal of Infectious Diseases 191: 2138–2148.PubMedCrossRef
12.
go back to reference Wittebole, X., S. Hahm, S.M. Coyle, A. Kumar, S.E. Calvano, and S.F. Lowry. 2007. Nicotine exposure alters in vivo human responses to endotoxin. Clinical and Experimental Immunology 147: 28–34.PubMed Wittebole, X., S. Hahm, S.M. Coyle, A. Kumar, S.E. Calvano, and S.F. Lowry. 2007. Nicotine exposure alters in vivo human responses to endotoxin. Clinical and Experimental Immunology 147: 28–34.PubMed
13.
go back to reference Wang, H., M. Yu, M. Ochani, et al. 2003. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421: 384–388.PubMedCrossRef Wang, H., M. Yu, M. Ochani, et al. 2003. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421: 384–388.PubMedCrossRef
14.
go back to reference de Jonge, W.J., E.P. van der Zanden, F.O. The, et al. 2005. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nature Immunology 6: 844–851.PubMedCrossRef de Jonge, W.J., E.P. van der Zanden, F.O. The, et al. 2005. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nature Immunology 6: 844–851.PubMedCrossRef
15.
go back to reference de Jonge, W.J., and L. Ulloa. 2007. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. British Journal of Pharmacology 151: 915–929.PubMedCrossRef de Jonge, W.J., and L. Ulloa. 2007. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. British Journal of Pharmacology 151: 915–929.PubMedCrossRef
16.
go back to reference Eliakim, R., F. Karmeli, D. Rachmilewitz, P. Cohen, and A. Fich. 1998. Effect of chronic nicotine administration on trinitrobenzene sulphonic acid-induced colitis. European Journal of Gastroenterology & Hepatology 10: 1013–1019.CrossRef Eliakim, R., F. Karmeli, D. Rachmilewitz, P. Cohen, and A. Fich. 1998. Effect of chronic nicotine administration on trinitrobenzene sulphonic acid-induced colitis. European Journal of Gastroenterology & Hepatology 10: 1013–1019.CrossRef
17.
go back to reference Karban, A., and R. Eliakim. 2007. Effect of smoking on inflammatory bowel disease: Is it disease or organ specific? World Journal of Gastroenterology 13: 2150–2152.PubMed Karban, A., and R. Eliakim. 2007. Effect of smoking on inflammatory bowel disease: Is it disease or organ specific? World Journal of Gastroenterology 13: 2150–2152.PubMed
18.
go back to reference Mabley, J.G., P. Pacher, G.J. Southan, A.L. Salzman, and C. Szabo. 2002. Nicotine reduces the incidence of type I diabetes in mice. The Journal of Pharmacology and Experimental Therapeutics 300: 876–881.PubMedCrossRef Mabley, J.G., P. Pacher, G.J. Southan, A.L. Salzman, and C. Szabo. 2002. Nicotine reduces the incidence of type I diabetes in mice. The Journal of Pharmacology and Experimental Therapeutics 300: 876–881.PubMedCrossRef
19.
go back to reference Carlsson, S., K. Midthjell, and V. Grill. 2004. Smoking is associated with an increased risk of type 2 diabetes but a decreased risk of autoimmune diabetes in adults: an 11-year follow-up of incidence of diabetes in the Nord-Trondelag Study. Diabetologia 47: 1953–1956.PubMedCrossRef Carlsson, S., K. Midthjell, and V. Grill. 2004. Smoking is associated with an increased risk of type 2 diabetes but a decreased risk of autoimmune diabetes in adults: an 11-year follow-up of incidence of diabetes in the Nord-Trondelag Study. Diabetologia 47: 1953–1956.PubMedCrossRef
20.
go back to reference Shi, F.D., W.H. Piao, Y.P. Kuo, D.I. Campagnolo, T.L. Vollmer, and R.J. Lukas. 2009. Nicotinic attenuation of central nervous system inflammation and autoimmunity. Journal of Immunology 182: 1730–1739.CrossRef Shi, F.D., W.H. Piao, Y.P. Kuo, D.I. Campagnolo, T.L. Vollmer, and R.J. Lukas. 2009. Nicotinic attenuation of central nervous system inflammation and autoimmunity. Journal of Immunology 182: 1730–1739.CrossRef
21.
go back to reference van Maanen, M.A., M.C. Lebre, T. van der Poll, et al. 2009. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis and Rheumatism 60: 114–122.PubMedCrossRef van Maanen, M.A., M.C. Lebre, T. van der Poll, et al. 2009. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis and Rheumatism 60: 114–122.PubMedCrossRef
22.
go back to reference Mishra, N.C., J. Rir-Sima-Ah, R.J. Langley, et al. 2008. Nicotine primarily suppresses lung Th2 but not goblet cell and muscle cell responses to allergens. Journal of Immunology 180: 7655–7663. Mishra, N.C., J. Rir-Sima-Ah, R.J. Langley, et al. 2008. Nicotine primarily suppresses lung Th2 but not goblet cell and muscle cell responses to allergens. Journal of Immunology 180: 7655–7663.
23.
go back to reference The, F.O., G.E. Boeckxstaens, S.A. Snoek, et al. 2007. Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology 133: 1219–1228.PubMedCrossRef The, F.O., G.E. Boeckxstaens, S.A. Snoek, et al. 2007. Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology 133: 1219–1228.PubMedCrossRef
24.
go back to reference Mabley, J.G., P. Pacher, and C. Szabo. 2009. Activation of the cholinergic antiinflammatory pathway reduces ricin-induced mortality and organ failure in mice. Molecular Medicine 15: 166–172.PubMedCrossRef Mabley, J.G., P. Pacher, and C. Szabo. 2009. Activation of the cholinergic antiinflammatory pathway reduces ricin-induced mortality and organ failure in mice. Molecular Medicine 15: 166–172.PubMedCrossRef
25.
go back to reference Bradford, M.M. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248–254.PubMedCrossRef Bradford, M.M. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248–254.PubMedCrossRef
26.
go back to reference Mabley, J.G., P. Pacher, L. Liaudet, et al. 2003. Inosine reduces inflammation and improves survival in a murine model of colitis. American Journal of Physiology. Gastrointestinal and Liver Physiology 284: G138–G144.PubMed Mabley, J.G., P. Pacher, L. Liaudet, et al. 2003. Inosine reduces inflammation and improves survival in a murine model of colitis. American Journal of Physiology. Gastrointestinal and Liver Physiology 284: G138–G144.PubMed
27.
go back to reference Liaudet, L., J.G. Mabley, P. Pacher, et al. 2002. Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Annals of Surgery 235: 568–578.PubMedCrossRef Liaudet, L., J.G. Mabley, P. Pacher, et al. 2002. Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Annals of Surgery 235: 568–578.PubMedCrossRef
28.
go back to reference Liaudet, L., P. Pacher, J.G. Mabley, et al. 2002. Activation of poly(ADP-ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. American Journal of Respiratory and Critical Care Medicine 165: 372–377.PubMed Liaudet, L., P. Pacher, J.G. Mabley, et al. 2002. Activation of poly(ADP-ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. American Journal of Respiratory and Critical Care Medicine 165: 372–377.PubMed
29.
go back to reference Rosas-Ballina, M., M. Ochani, W.R. Parrish, et al. 2008. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proceedings of the National Academy of Sciences of the United States of America 105: 11008–11013.PubMedCrossRef Rosas-Ballina, M., M. Ochani, W.R. Parrish, et al. 2008. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proceedings of the National Academy of Sciences of the United States of America 105: 11008–11013.PubMedCrossRef
30.
go back to reference Gwilt, C.R., L.E. Donnelly, and D.F. Rogers. 2007. The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation? Pharmacology & Therapeutics 115: 208–222.CrossRef Gwilt, C.R., L.E. Donnelly, and D.F. Rogers. 2007. The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation? Pharmacology & Therapeutics 115: 208–222.CrossRef
31.
go back to reference Su, X., J.W. Lee, Z.A. Matthay, et al. 2007. Activation of the {alpha}7 nAChR reduces acid-induced acute lung injury in mice and rats. American Journal of Respiratory Cell and Molecular Biology 37: 186–192.PubMedCrossRef Su, X., J.W. Lee, Z.A. Matthay, et al. 2007. Activation of the {alpha}7 nAChR reduces acid-induced acute lung injury in mice and rats. American Journal of Respiratory Cell and Molecular Biology 37: 186–192.PubMedCrossRef
32.
go back to reference Pavlov, V.A., W.R. Parrish, M. Rosas-Ballina, et al. 2009. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain, Behavior, and Immunity 23: 41–45.PubMedCrossRef Pavlov, V.A., W.R. Parrish, M. Rosas-Ballina, et al. 2009. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain, Behavior, and Immunity 23: 41–45.PubMedCrossRef
33.
go back to reference Hofer, S., C. Eisenbach, I.K. Lukic, et al. 2008. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Critical Care Medicine 36: 404–408.PubMedCrossRef Hofer, S., C. Eisenbach, I.K. Lukic, et al. 2008. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Critical Care Medicine 36: 404–408.PubMedCrossRef
34.
go back to reference Parrish, W.R., M. Rosas-Ballina, M. Gallowitsch-Puerta, et al. 2008. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Molecular Medicine 14: 567–574.PubMedCrossRef Parrish, W.R., M. Rosas-Ballina, M. Gallowitsch-Puerta, et al. 2008. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Molecular Medicine 14: 567–574.PubMedCrossRef
35.
go back to reference Yoshikawa, H., M. Kurokawa, N. Ozaki, et al. 2006. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clinical and Experimental Immunology 146: 116–123.PubMedCrossRef Yoshikawa, H., M. Kurokawa, N. Ozaki, et al. 2006. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clinical and Experimental Immunology 146: 116–123.PubMedCrossRef
36.
go back to reference Sugano, N., K. Shimada, K. Ito, and S. Murai. 1998. Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kappaB activation. Biochemical and Biophysical Research Communications 252: 25–28.PubMedCrossRef Sugano, N., K. Shimada, K. Ito, and S. Murai. 1998. Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kappaB activation. Biochemical and Biophysical Research Communications 252: 25–28.PubMedCrossRef
37.
go back to reference Ware, L.B. 2006. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Seminars in Respiratory and Critical Care Medicine 27: 337–349.PubMedCrossRef Ware, L.B. 2006. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Seminars in Respiratory and Critical Care Medicine 27: 337–349.PubMedCrossRef
38.
go back to reference Blanchet, M.R., E. Israel-Assayag, and Y. Cormier. 2004. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. American Journal of Respiratory and Critical Care Medicine 169: 903–909.PubMedCrossRef Blanchet, M.R., E. Israel-Assayag, and Y. Cormier. 2004. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. American Journal of Respiratory and Critical Care Medicine 169: 903–909.PubMedCrossRef
39.
go back to reference Abraham, E., J. Arcaroli, and R. Shenkar. 2001. Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5′-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia. Journal of Immunology 166: 522–530. Abraham, E., J. Arcaroli, and R. Shenkar. 2001. Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5′-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia. Journal of Immunology 166: 522–530.
40.
go back to reference Sugita, A., H. Ogawa, M. Azuma, et al. 2009. Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. International Archives of Allergy and Immunology 148: 186–198.PubMedCrossRef Sugita, A., H. Ogawa, M. Azuma, et al. 2009. Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. International Archives of Allergy and Immunology 148: 186–198.PubMedCrossRef
41.
go back to reference Miyazaki, E., S. Nureki, E. Ono, et al. 2007. Circulating thymus- and activation-regulated chemokine/CCL17 is a useful biomarker for discriminating acute eosinophilic pneumonia from other causes of acute lung injury. Chest 131: 1726–1734.PubMedCrossRef Miyazaki, E., S. Nureki, E. Ono, et al. 2007. Circulating thymus- and activation-regulated chemokine/CCL17 is a useful biomarker for discriminating acute eosinophilic pneumonia from other causes of acute lung injury. Chest 131: 1726–1734.PubMedCrossRef
Metadata
Title
Nicotine Exerts an Anti-inflammatory Effect in a Murine Model of Acute Lung Injury
Authors
Jon Mabley
Sevelanne Gordon
Pal Pacher
Publication date
01-08-2011
Publisher
Springer US
Published in
Inflammation / Issue 4/2011
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9228-x

Other articles of this Issue 4/2011

Inflammation 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.